Breaking News Instant updates and real-time market news.

EXEL

Exelixis

$13.18

0.06 (0.46%)

04:47
10/07/16
10/07
04:47
10/07/16
04:47

Exelixis announces results for cabozantinib phase 1 combination trial

Exelixis announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors. The findings will be presented during a poster discussion session on October 9 at the European Society for Medical Oncology 2016 Congress, which is being held in Copenhagen, October 7-11. "The treatment landscape for advanced, intractable cancers such as metastatic urothelial carcinoma is continuously evolving and the use of combination therapies may improve outcomes for patients in need of new options," said Andrea Apolo, M.D., Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, the principal investigator of the trial. "Our previous correlative studies have demonstrated that cabozantinib has immunomodulatory properties that may counteract tumor-induced immunosuppression, providing the rationale for this trial.1,2 These promising early stage clinical findings support further investigation of cabozantinib in combination with nivolumab in a number of genitourinary tumors." Between July 2015 and September 2016, 24 patients were accrued with metastatic urothelial carcinoma, urachal adenocarcinoma, squamous cell carcinoma of the bladder or urethra, germ cell tumor, castration-resistant prostate cancer, renal cell carcinoma, or trophoblastic tumor and were treated in Part I of the study, which evaluated the combination of cabozantinib and nivolumab at four dose levels. The median number of prior systemic therapies was 3, and 10 patients had received 4 or more prior therapies. The objective response rate was 43 percent among the 23 patients who were evaluable for response, with one complete response and nine partial responses. Four of six patients with urothelial cancer achieved a response. The recommended doses for the ongoing expansion cohorts were determined to be cabozantinib at 40 mg daily and nivolumab at 3 mg/kg once every 2 weeks. Part II of the phase 1 trial examining the use of the triplet combination of cabozantinib, nivolumab, and ipilimumab is also ongoing.

  • 07

    Oct

  • 10

    Oct

  • 10

    Oct

EXEL Exelixis
$13.18

0.06 (0.46%)

08/04/16
STFL
08/04/16
NO CHANGE
STFL
Exelixis price target raised to $12 from $10 at Stifel
Stifel analyst Stephen Willey raised his price target on Exelixis after the company reported significantly better than expected Cabometyx and residual/off-label Cometriq sales into the newly launched indication of refractory renal cell carcinom. Willey expects the results to improve investors' confidence towards the company's growth outlook, and he says that anticipation of front-line CABOSUN results places a near-term floor on the stock. The analyst keeps a Buy rating on the shares.
08/22/16
GSCO
08/22/16
NO CHANGE
GSCO
Goldman lists companies to be in focus after Medivation deal
After Pfizer (PFE) announced it has agreed to acquire Medivation (MDVN) for $81.50 per share in cash, Goldman Sachs analyst Salveen Richter said he expects a focus on other commercial small-to-mid-cap cancer companies, including Incyte (INCY), Seattle Genetics (SGEN), ARIAD (ARIA) and Exelixis (EXEL). Also noting that Sanofi (SNY), which was pursuing Medivation, has recently suggested an interest in a rare disease transaction up to potentially as large as $20B, he would expect rare disease companies of that size - such as BioMarin (BMRN), Amicus (FOLD) and Ultragenyx (RARE) - to be in focus as well.
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Exelixis selloff overdone, says Leerink
09/28/16
LEER
09/28/16
NO CHANGE
LEER
Outperform
Exelixis selloff based on ESMO abstracts overdone, says Leerink
Leerink analyst Michael Schmidt believes Exelixis' selloff following the publication of ESMO poster abstracts is overdone. The analyst notes that abstract includes updated data from a Phase Ib trial evaluating the combination of axitinib with pembrolizumab and appears to have sparked competitive concerns for Exelixis. However, he believes it is highly premature to draw conclusions at this point on the company's Cabometyx' market opportunity or potential in Renal Cell Carcinoma. Schmidt reiterates an Outperform rating on the shares. In afternoon trading, Exelixis' stock has dropped over 15% to $13.12 per share.

TODAY'S FREE FLY STORIES

OXFD

Oxford Immunotec

$15.34

0.2 (1.32%)

16:45
06/22/17
06/22
16:45
06/22/17
16:45
Hot Stocks
Oxford Immunotec announces reimbursement decision for T-SPOT test in France »

Oxford Immunotec Global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVH

Evolent Health

$25.90

-0.85 (-3.18%)

16:40
06/22/17
06/22
16:40
06/22/17
16:40
Syndicate
Evolent Health files to sell 4.5M shares of Class A common stock for holders »

Goldman Sachs & Co.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDRA

Idera Pharmaceuticals

$1.73

0.02 (1.17%)

16:34
06/22/17
06/22
16:34
06/22/17
16:34
Hot Stocks
Idera announces FDA orphan drug designation for IMO-2125 for melanoma treatment »

Idera Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Fed Balance Sheet Level data reported »

Week of 6/21 Fed Balance…

16:33
06/22/17
06/22
16:33
06/22/17
16:33
General news
Money Supply M2 Weekly Change data reported »

Week of 6/12 Money Supply…

MGM

MGM Resorts

$33.25

0.29 (0.88%)

16:33
06/22/17
06/22
16:33
06/22/17
16:33
Hot Stocks
Breaking Hot Stocks news story on MGM Resorts »

Soroban Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

, BAC

Bank of America

$22.93

-0.2 (-0.86%)

16:32
06/22/17
06/22
16:32
06/22/17
16:32
Hot Stocks
All 34 banks exceed minimum requirements of Fed Stress Test »

Publicly traded banks…

GS

Goldman Sachs

$219.77

-2.72 (-1.22%)

BAC

Bank of America

$22.93

-0.2 (-0.86%)

C

Citi

$63.62

-0.21 (-0.33%)

WFC

Wells Fargo

$52.49

-0.49 (-0.92%)

JPM

JPMorgan

$87.02

-0.1 (-0.11%)

MS

Morgan Stanley

$44.61

-0.3 (-0.67%)

USB

U.S. Bancorp

$51.30

-0.7 (-1.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 14

    Jul

  • 14

    Jul

  • 18

    Jul

  • 19

    Jul

  • 25

    Jul

  • 12

    Oct

  • 12

    Oct

  • 17

    Oct

  • 18

    Oct

  • 15

    Jan

  • 17

    Jan

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

16:30
06/22/17
06/22
16:30
06/22/17
16:30
Options
Preliminary option volume of 14.6M today »

Preliminary option volume…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

, GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

16:27
06/22/17
06/22
16:27
06/22/17
16:27
Hot Stocks
YouTube developing 'VR180' video format, says team working with camera makers »

Alphabet's (GOOG)…

GOOG

Alphabet

$957.09

-2.36 (-0.25%)

GOOGL

Alphabet Class A

$976.62

-1.97 (-0.20%)

LNVGY

Lenovo

$12.85

0.059 (0.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 19

    Jul

BBBY

Bed Bath & Beyond

$33.73

0.07 (0.21%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

NAT

Nordic American Tankers

$6.00

-0.02 (-0.33%)

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Syndicate
Breaking Syndicate news story on Nordic American Tankers »

Nordic American Tankers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JONE

Jones Energy

16:25
06/22/17
06/22
16:25
06/22/17
16:25
Hot Stocks
Jones Energy exits Arkoma Basin with non-core asset sales »

Jones Energy announced …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

, CIR

CIRCOR

$58.20

2.98 (5.40%)

16:24
06/22/17
06/22
16:24
06/22/17
16:24
Hot Stocks
Breaking Hot Stocks news story on GAMCO Investors, CIRCOR »

Gabelli reports 15.94%…

GBL

GAMCO Investors

$29.89

0.27 (0.91%)

CIR

CIRCOR

$58.20

2.98 (5.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:23
06/22/17
06/22
16:23
06/22/17
16:23
Hot Stocks
Bed Bath & Beyond says saw increased 'softness in transactions in stores' in Q1 »

At this time, Bed Bath…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

CPE

Callon Petroleum

$9.69

-0.06 (-0.62%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Callon Petroleum appoints Correne S. Loeffler as Interim CFO »

Callon Petroleum has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 14

    Nov

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:21
06/22/17
06/22
16:21
06/22/17
16:21
Hot Stocks
Bed Bath & Beyond repurchased approximately $127M of common stock in Q1 »

During the fiscal 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SGH

Smart Global

$16.20

0.45 (2.86%)

16:20
06/22/17
06/22
16:20
06/22/17
16:20
Earnings
Smart Global sees Q4 EPS 62c-66c, consensus 57c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
SYNNEX approves $300M share repurchase program »

SYNNEX has approved an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

AAL

American Airlines

$48.97

0.54 (1.12%)

, HCA

HCA Holdings

$86.14

2.09 (2.49%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
General news
On The Fly: Top stock stories for Thursday »

Stocks began the session…

AAL

American Airlines

$48.97

0.54 (1.12%)

HCA

HCA Holdings

$86.14

2.09 (2.49%)

PLNT

Planet Fitness

$23.95

0.38 (1.61%)

THC

Tenet

$18.89

1.21 (6.84%)

UNH

UnitedHealth

$186.50

1.58 (0.85%)

HUM

Humana

$237.00

0.79 (0.33%)

AET

Aetna

$152.98

0.88 (0.58%)

RAD

Rite Aid

$3.08

-0.11 (-3.45%)

WBA

Walgreens Boots Alliance

$76.37

-1.75 (-2.24%)

ORCL

Oracle

$50.30

3.97 (8.57%)

SPLS

Staples

$9.20

0.54 (6.24%)

JWN

Nordstrom

$47.48

1.4 (3.04%)

WB

Weibo

$72.25

-4.71 (-6.12%)

SCS

Steelcase

$14.10

-2.2 (-13.50%)

ACN

Accenture

$122.08

-5.03 (-3.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 22

    Jun

  • 22

    Jun

  • 26

    Jun

  • 28

    Jun

  • 29

    Jun

  • 07

    Jul

  • 18

    Jul

  • 23

    Aug

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:19
06/22/17
06/22
16:19
06/22/17
16:19
Hot Stocks
Bed Bath & Beyond reports Q1 SSS from customer-facing digital channels up 20%+ »

Comparable sales in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.96

1.62 (1.35%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
SYNNEX sees Q3 non-GAAP EPS $1.94-$2.02, consensus $1.92 »

Sees Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:18
06/22/17
06/22
16:18
06/22/17
16:18
Earnings
Bed Bath & Beyond reports Q1 EPS 53c, consensus 66c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

SNX

SYNNEX

$121.84

1.51 (1.25%)

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Earnings
SYNNEX reports Q2 non-GAAP EPS $2.08, consensus $1.79 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

$NSD

NASDAQ Market Internals

16:17
06/22/17
06/22
16:17
06/22/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$33.74

0.08 (0.24%)

16:16
06/22/17
06/22
16:16
06/22/17
16:16
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.